Comparative efficacy of @entity9695 and XXXX on inflammatory events in third molar surgery: a split-mouth, prospective, randomized, double-blind study.

@entity1 @entity7988 @entity2133 @entity4 @entity158 @entity9695
UNASSIGNED: This study aimed to compare the effect of @entity9695 and @entity7988 on inflammatory parameters related to the surgical removal of third molars. A split-mouth, prospective, randomized, double-blind study was conducted in @entity1 undergoing removal of four third molars. Eighteen eligible @entity1 were allocated to one of two groups to receive treatment two times a day with either @entity7988 100mg or @entity9695 100mg for a period of 3 days. The rescue medication intake (number) and @entity158 intensity were evaluated at 6, 12, 24, and 48h, and at 7 days postoperatively. Swelling and @entity2133 opening were evaluated at 24h, 72h, and 7 days postoperatively. The peak @entity158 score occurred at 6h after surgery in the @entity9695 group and at 12h in the @entity7988 group. There was no statistically significant difference between the groups, although @entity158 relief was observed after 48h in the @entity9695 group and after 7 days in the @entity7988 group. For each group, there was a statically significant difference in @entity158 scores among the studied periods (P<0.0001). None of the @entity1 required rescue medication. There was a statistically significant difference in @entity2133 opening between the preoperative and postoperative periods (P<0.0001). @entity7988 and @entity9695 were effective at controlling @entity158 , @entity4 , and trismus after the surgical removal of third molars.
